<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16206501
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     10
    </month>
    <day>
     06
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2005
    </year>
    <month>
     11
    </month>
    <day>
     22
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2008
    </year>
    <month>
     11
    </month>
    <day>
     21
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1542-3565
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       3
      </volume>
      <issue>
       7
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Jul
       </month>
      </pubdate>
     </journalissue>
     <title>
      Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
     </title>
     <isoabbreviation>
      Clin. Gastroenterol. Hepatol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses.
    </articletitle>
    <pagination>
     <medlinepgn>
      679-86
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND &amp; AIMS" nlmcategory="OBJECTIVE">
      Undiagnosed patients with symptoms of celiac sprue often present to physicians after establishing dietary gluten exclusion. Although they must resume a gluten-containing diet for evaluation, there are no guidelines regarding duration of the gluten challenge, gluten dose, or monitoring parameters. We investigated the effects of a short-term gluten challenge in asymptomatic treated adult celiac patients on intestinal absorption and celiac antibody tests.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Eight adult asymptomatic celiac patients consumed either 5 or 10 g of partially hydrolyzed gluten per day in an orange juice mixture for 21 days while maintaining their usual gluten-free diet. A symptom questionnaire, serum antibodies (antigliadin immunoglobulin [Ig]A and antitransglutaminase IgA and IgG), D-xylose urine excretion test, and 72-hour quantitative fecal fat test were monitored.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Two patients (25%) had at least 1 abnormal celiac antibody test at baseline. There was no increase in antibodies during gluten exposure compared with baseline for any of the patients (P &gt; .05). At baseline, 1 patient had abnormal urine xylose excretion, and 3 patients had abnormal fecal fat values. At day 15 of gluten challenge, all patients had reduced xylose absorption compared with baseline (P = .0019), and 5 of 8 participants (63%) reduced their xylose excretion to the abnormal range. Seven of 8 patients (88%) had increased fecal fat excretion at day 15 (P = .026), and 6 of these (75%) had steatorrhea by day 15.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Short-term gluten challenge in asymptomatic adult celiac patients produces carbohydrate and fat malabsorption but does not increase transglutaminase and antigliadin antibody titers.
     </abstracttext>
    </abstract>
    <affiliation>
     Celiac Sprue Research Foundation, Palo Alto, California 94304-1193, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Pyle
      </lastname>
      <forename>
       Gail G
      </forename>
      <initials>
       GG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Paaso
      </lastname>
      <forename>
       Brian
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Anderson
      </lastname>
      <forename>
       Barbara E
      </forename>
      <initials>
       BE
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Allen
      </lastname>
      <forename>
       Diane
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Marti
      </lastname>
      <forename>
       Thomas
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Khosla
      </lastname>
      <forename>
       Chaitan
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gray
      </lastname>
      <forename>
       Gary M
      </forename>
      <initials>
       GM
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Clin Gastroenterol Hepatol
    </medlineta>
    <nlmuniqueid>
     101160775
    </nlmuniqueid>
    <issnlinking>
     1542-3565
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunoglobulin A
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunoglobulin G
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      8002-80-0
     </registrynumber>
     <nameofsubstance>
      Glutens
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 2.3.2.13
     </registrynumber>
     <nameofsubstance>
      Transglutaminases
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Clin Gastroenterol Hepatol. 2005 Jul;3(7):629-30
     </refsource>
     <pmid version="1">
      16206492
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antibody Formation
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Celiac Disease
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dose-Response Relationship, Drug
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glutens
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoglobulin A
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoglobulin G
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Intestinal Absorption
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Transglutaminases
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      10
     </month>
     <day>
      7
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2005
     </year>
     <month>
      12
     </month>
     <day>
      13
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      10
     </month>
     <day>
      7
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     16206501
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

